Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator's Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell Lymphoma
- Conditions
- Neoplasms
- Registration Number
- KCT0005381
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 86
Patients must satisfy all following criteria to be enrolled in the study:
1. Patient is = 18 years of age at the time of signing the informed consent form (ICF).
2. Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted.
3. Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
4. Patient had local diagnosed peripheral T cell lymphoma (PTCL) with T-follicular helper (TFH) phenotype according to the criteria of the latest WHO classification based on a surgical lymph node biopsy or needle core biopsy including any one of:
• Angioimmunoblastic T cell lymphoma (AITL)
• Follicular T cell lymphoma
• Nodal peripheral T-cell lymphoma with TFH phenotype
There should be a documented expression of minimum two TFH markers by the tumoral cells among this panel of markers: CD10, CXCL13, PD1, ICOS, and BCL6 by the tumoral cells by immunohistochemistry. Biopsy at relapse or progression is not mandatory, but highly encouraged on a surgical or needle core biopsy, and diagnostic tissue should be available for central pathology review and ancillary molecular studies.
Local pathology report should be reviewed by the sponsor’s medical monitor prior to enrollment.
5. ECOG performance status 0 to 3
6. Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below).
7. Meet the following lab criteria:
a. ANC = 1,5 x 109/L (= 1 x 109/L if BM involvement by lymphoma)
b. Platelet = 75 x 109/L (= 50 x 109/L if BM involvement by lymphoma)
c. Hemoglobin = 8 g/dL.
8. Anticipated life expectancy at least 3 months
9. At least one measurable lesion on CT that is greater than 1.5 cm in the longest diameter for nodal lesions and greater than 1.0 cm in the longest diameter for extranodal lesions. The lesion must be measurable in two perpendicular dimensions. Patients with only cutaneous disease will be excluded.
10. Female patient of childbearing potential (FCBP) may participate, providing she meets the following conditions:
Have two negative pregnancy tests as verified by the investigator prior to starting study treatment: serum pregnancy test at Screening and negative serum or urine pregnancy test (investigator’s discretion) within 72 hours prior to starting study treatment (Cycle 1 Day 1). She must agree to ongoing pregnancy testing during the study (before beginning each subsequent cycle of treatment), and 28 days after the last dose of study treatment. This applies even if the patient practices complete abstinence from heterosexual contact.
Agrees to practice true abstinence (which must be reviewed monthly and source documented) or agree to the use of highly effective methods of contraception from 28 days prior to study treatment, and must agree to continue using such precautions during study treatment (including dose interruptions) and for up to 6 months after the last study drug administration. True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptom-thermal, post ovulation methods) and withdrawal are not acceptable methods of contraception. Cessation of contraception after this point should be discussed with a responsible physician.
Agrees to a
Presence of any of the following will exclude a patient from enrollment:
1. Clinical evidence of central nervous system involvement by lymphoma. Patients with suspicion of CNS involvement must undergo neurologic evaluation and CT/MRI of head and lumbar puncture to exclude CNS disease.
2. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator’s decision)
3. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
4. Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of positive HTLV1 serology or of active Hepatitis B Virus (HBV) infection defined as:
- HBs Ag positive
- HBs Ag negative, anti-HBs antibody positive and/or anti-HBc antibody positive with detectable viral DNA
5. Impaired renal function (calculated MDRD or Cockcroft-Gault Creatinine Clearance < 30 ml/min) or impaired liver function tests (Serum total bilirubin level > 2.0 mg/dl [34 µmol/L] (except in case of Gilbert’s Syndrome, or documented liver or pancreatic involvement by lymphoma), Serum transaminases (AST or ALT) > 3 upper normal limits) unless they are related to the lymphoma.
6. Active malignancy other than the one treated in this research. Prior history of malignancies, other than low risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) at Screening (with less than 5% blasts in bone marrow), unless the patient has been free of the disease for = 3 years. However, patients with the following history/concurrent conditions are allowed:
a. Basal or squamous cell carcinoma of the skin
b. Carcinoma in situ of the cervix
c. Carcinoma in situ of the breast
d. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, metastasis [TNM] clinical staging system
e. Early-stage gastric cancer suitable for endoscopic mucosal resection or endoscopic submucosal dissection
7. Treatment with any investigational drug within 5 half-lives before planned first cycle of study treatment and during the study. Ongoing medically significant adverse events from previous treatment, regardless of the time period
8. Prior exposure to azacitidine and/ or any other demethylating agent (eg, decitabine)
9. Prior exposure to planned investigator’s choice therapy (eg, prior exposure to gemcitabine is an exclusion if gemcitabine is the planned investigator’s choice therapy prior to randomization)
10. Concurrent use of corticosteroids unless the patient is on a stable or decreasing dose for = 1 week prior to informed consent form signature.
11. Knowing or suspected hypersensitivity to active substance or to any of the excipients.
12. Pregnant, planning to become pregnant, or lactating woman
13. Candidate for hematopoietic stem cell transplantation
14. History of active inflammatory bowel disease (eg, Crohn's disease, ulcerative
colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel
removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the oral azacitidine and/or predispose the patient to an increased risk of gastrointestinal toxicity per investigators’ discretion. Any condition causing inability to swallow tablets.
15. Signi
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival (PFS), using local assessment of progressive disease according to Lugano Response Criteria (2014)
- Secondary Outcome Measures
Name Time Method Overall Survival (OS);Overall response rate (ORR);Complete response rate (CRR);Duration of response;Time to response;PFS2 using local assessment of progressive disease;HRQOL endpoints EORTC QLQ-C30